BiCNU

BiCNU

carmustine

Manufacturer:

Emcure

Distributor:

Advagen
Concise Prescribing Info
Contents
Carmustine
Indications/Uses
Established combination therapy w/ other approved chemotherapeutic agents in glioblastoma; Hodgkin's & non-Hodgkin's lymphoma (2nd-line, combination therapy).
Dosage/Direction for Use
Previously untreated patient 150-200 mg/m2 IV every 6 wk. May be given as a single dose or divided into daily inj of 75-100 mg/m2 on 2 successive days. Dose reduction w/ other myelosuppressive drugs or in whom bone marrow reserve is depleted. Doses subsequent to initial dose should be adjusted according to the hematologic response of the patient to the preceding dose.
Contraindications
Special Precautions
Monitor complete blood counts wkly for at least 6 wk after a dose. Cases of fatal pulmonary toxicity. Close monitoring of the infusion site for possible infiltration during drug administration is recommended due to possibility of extravasation. Monitor long-term development of secondary malignancies. Ocular toxicity. Advise females of reproductive potential to use highly effective contraception during & after treatment for at least 6 mth after therapy & at least 3 mth after therapy for males of reproductive potential. Pregnancy. Discontinue use during lactation. Childn. Elderly.
Adverse Reactions
Tachycardia, chest pain; conjunctival edema & hemorrhage, blurred vision & loss of depth perception; nausea, vomiting, anorexia, diarrhea; increased transaminase, alkaline phosphatase & bilirubin levels; opportunistic infection (including w/ fatal outcome); acute leukemia, bone marrow dysplasias; progressive azotemia, decreased kidney size, renal failure; headaches, encephalopathy, seizures; pneumonitis, interstitial lung disease; gynecomastia; burning sensation, hyperpigmentation, swelling, pain, erythema, skin necrosis, alopecia, allergic reaction; veno-occlusive disease.
Drug Interactions
Risk of myelosuppression w/ cimetidine. Induced metabolism w/ phenobarb. May reduce serum conc of phenytoin.
ATC Classification
L01AD01 - carmustine ; Belongs to the class of alkylating agents, nitrosoureas. Used in the treatment of cancer.
Presentation/Packing
Form
BiCNU powd for inj 100 mg
Packing/Price
(+ 3 mL sterile diluent vial) 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in